Literature DB >> 23735777

Pathology and disease mechanisms in different stages of multiple sclerosis.

Hans Lassmann1.   

Abstract

In this review the differences in pathology and disease mechanisms between early and late stages of multiple sclerosis are discussed. The data suggest that affection of the brain is different, depending on the location of lesions, on the stage of the disease, when lesions arise, and on inter-individual differences between patients. We suggest that in the early stage of the disease new lesions are formed by new waves of inflammatory cells, entering the central nervous system from the circulation and giving rise to focal demyelinated plaques in the white and gray matter. In contrast, at late stages of the disease inflammation decreases, but the susceptibility of the target tissue for neurodegeneration increases. New data suggest that mitochondrial injury, mediated through oxidative injury, is in the center of the pathogenetic events leading to brain damage in multiple sclerosis patients.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Demyelination; Inflammation; Mitochondria; Multiple sclerosis; Neurodegeneration; Oxidative injury

Mesh:

Year:  2013        PMID: 23735777     DOI: 10.1016/j.jns.2013.05.010

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  62 in total

1.  Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.

Authors:  Yong Wang; Peng Sun; Qing Wang; Kathryn Trinkaus; Robert E Schmidt; Robert T Naismith; Anne H Cross; Sheng-Kwei Song
Journal:  Brain       Date:  2015-02-26       Impact factor: 13.501

2.  Multiple sclerosis: Oral laquinimod for MS--bringing the brain into focus.

Authors:  Wolfgang Brück; Timothy Vollmer
Journal:  Nat Rev Neurol       Date:  2013-11-26       Impact factor: 42.937

3.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

4.  Human retrovirus pHEV-W envelope protein and the pathogenesis of multiple sclerosis.

Authors:  Robert P Lisak
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-09       Impact factor: 11.205

Review 5.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

6.  Hemoglobin as a source of iron overload in multiple sclerosis: does multiple sclerosis share risk factors with vascular disorders?

Authors:  Vladimir V Bamm; George Harauz
Journal:  Cell Mol Life Sci       Date:  2014-02-07       Impact factor: 9.261

Review 7.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

Review 8.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

9.  Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis.

Authors:  Iraj Ragerdi Kashani; Zahra Rajabi; Mohammad Akbari; Gholamreza Hassanzadeh; Alireza Mohseni; Mohammadtaha Kouchakinejad Eramsadati; Kheirollah Rafiee; Cordian Beyer; Markus Kipp; Adib Zendedel
Journal:  Exp Brain Res       Date:  2014-05-06       Impact factor: 1.972

10.  Oligodendrocytes engineered with migratory proteins as effective graft source for cell transplantation in multiple sclerosis.

Authors:  Ike de la Pena; Mibel Pabon; Sandra Acosta; Paul R Sanberg; Naoki Tajiri; Yuji Kaneko; Cesar V Borlongan
Journal:  Cell Med       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.